June Bray - 02 Jan 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Reporting relationship: Director
Issuer ticker: QNCX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 17:59:06 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Brendan Hannah as attorney-in-fact for June Bray

Filing notes and source

Key filing fact

June Bray filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 21 Jan 2026.

Key facts

This page summarizes June Bray's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 17:59.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001845487 Primary reporting owner

Bray June

Relationship: Director
Address: C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Signature: /s/ Brendan Hannah as attorney-in-fact for June Bray
Signature date: 21 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNCX transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +18,724
Change %
Price: $0.000000
Shares after: 18,724
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 18,724
Exercise price: $3.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.